Patents Assigned to Lovelace Respiratory Research Institute
-
Patent number: 9512483Abstract: The present invention provides for a method to monitor the health of a subject. The method includes obtaining a test sample from the patient. A first probe specific for a CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample. The probe contacts the test sample. The DNA of interest from the test sample is isolated. A second stage probe specific for a second CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample to form a second stage PCR product. The DNA is analyzed for hypermethylation of the promoter region for at least one of p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK.Type: GrantFiled: July 10, 2006Date of Patent: December 6, 2016Assignee: LOVELACE RESPIRATORY RESEARCH INSTITUTEInventor: Steven A. Belinsky
-
Patent number: 9121048Abstract: Methods, kits, and compositions are disclosed for vaccinating a human or animal against human rhinovirus infection. Also provided are methods of using a cotton rat model for identifying and testing vaccines and therapeutic agents that prevent or ameliorate human rhinovirus infection.Type: GrantFiled: September 13, 2013Date of Patent: September 1, 2015Assignees: Sigmovir Biosystems, Inc., Lovelace Respiratory Research InstituteInventors: Jorge C. G. Blanco, Adriana E. Kajon
-
Publication number: 20110053894Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.Type: ApplicationFiled: April 17, 2007Publication date: March 3, 2011Applicant: LOVELACE RESPIRATORY RESEARCH INSTITUTEInventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
-
Publication number: 20110014625Abstract: A system and method for predicting the health of a subject comprising obtaining nucleic acid sequence data about the subject. Identifying at least one polymorphic risk marker associated with a change in promoter methylation of a gene associated with lung cancer; and predicting the health of the subject from a presence of at least one polymorphic risk marker identified and kits associated therewith.Type: ApplicationFiled: March 16, 2009Publication date: January 20, 2011Applicant: LOVELACE RESPIRATORY RESEARCH INSTITUTEInventors: Steven A. Belinsky, Shuguang Leng
-
Publication number: 20080241842Abstract: The present invention provides for a method to monitor the health of a subject. The method includes obtaining a test sample from the patient. A first probe specific for a CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample. The probe contacts the test sample. The DNA of interest from the test sample is isolated. A second stage probe specific for a second CpG promoter region of a biomarker selected from p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample to form a second stage PCR product. The DNA is analyzed for hypermethylation of the promoter region for at least one of p16, MGMT, PAX-?, PAX5-?, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK.Type: ApplicationFiled: July 10, 2006Publication date: October 2, 2008Applicant: LOVELACE RESPIRATORY RESEARCH INSTITUTEInventor: Steven A. Belinsky
-
Patent number: 7214485Abstract: A molecular marker-based method for monitoring and detecting cancer in humans. Aberrant methylation of gene promoters is a marker for cancer risk in humans. A two-stage, or “nested” polymerase chain reaction method is disclosed for detecting methylated DNA sequences at sufficiently high levels of sensitivity to permit cancer screening in biological fluid samples, such as sputum, obtained non-invasively. The method is for detecting the aberrant methylation of the p16 gene, O 6-methylguanine-DNA methyltransferase gene, Death-associated protein kinase gene, RAS-associated family 1 gene, or other gene promoters. The method offers a potentially powerful approach to population-based screening for the detection of lung and other cancers.Type: GrantFiled: August 24, 2001Date of Patent: May 8, 2007Assignee: Lovelace Respiratory Research InstituteInventors: Steven A. Belinsky, William A. Palmisano
-
Publication number: 20070037156Abstract: A method for genetic testing relating to chronic obstructive pulmonary disease (COPD), including testing for a single nucleotide polymorphism within the metal loproteinase-9 gene, an exon 6, codon 279 Gln/Arg polymorphism, where in presence of the variant polymorphism, particularly homozygous presence, is predictive of susceptibility to COPD. Further provided are methods of selecting patients for specific therapies and methods of drug development and discovery for treatment and prevention of COPD.Type: ApplicationFiled: August 11, 2004Publication date: February 15, 2007Applicant: Lovelace Respiratory Research InstituteInventors: Yohannes Tesfaigzi, Steven Belinsky
-
Publication number: 20040248171Abstract: PAX5 alpha and PAX5 beta and other genes as markers for cancer detection. A PCR-based technique of methylated CpG island amplification, followed by representational difference analysis, for identifying genes methylated in human cancer. The genes PAX5 alpha and PAX5 beta, novel loop helix loop protein, and a novel gene 2, and beta3 genes when methylated serve as markers for detecting, monitoring, diagnosing and prognosticating breast, colon, and lung cancer in humans. Amplification methods, including primer sequences for methylation specific polymerase chain reaction, are disclosed.Type: ApplicationFiled: March 25, 2004Publication date: December 9, 2004Applicant: Lovelace Respiratory Research InstituteInventors: William A. Palmisano, Steven A. Belinsky
-
Patent number: 6121299Abstract: This invention relates to methods of modulating inflammation in mammals. Inflammation is modulated by regulating the cytochrome P-450 pathway. Inflammation is reduced by treating the subject with substances, such as bezafibrate and clofibrate, which induce the P-450 pathway. Inflammation is promoted by treating the subject with substances, such as proadifen, econazole, and clotrimazole, which inhibit the cytochrome P-450 pathway.Type: GrantFiled: March 30, 1999Date of Patent: September 19, 2000Assignee: Lovelace Respiratory Research InstituteInventors: Wieslaw Kozak, Matthew J. Kluger, Yohannes Tesfaigzi
-
Patent number: 6003512Abstract: An apparatus and method for aerosolizing and dispensing powders utilizing the forces of pressurizing and depressurizing gas loaded into powder agglomerates located in an enclosed powder chamber. Methods include administering peptides, genes, vitamins, and polymers into the peripheral lung. Also describes powder supply apparatus and method for single dose and repetitive applications.Type: GrantFiled: November 12, 1998Date of Patent: December 21, 1999Assignee: Lovelace Respiratory Research InstituteInventor: Per Magnus Gerde